SynthesisJournal of the American Heart Association2018
Closure, Anticoagulation, or Antiplatelet Therapy for Cryptogenic Stroke With Patent Foramen Ovale: Systematic Review of Randomized Trials, Sequential Meta-Analysis, and New Insights From the CLOSE Study.
Synthesis in Journal of the American Heart Association, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 72 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Pioneering Advancements in Cardiocerebrovascular Interactions in the Asia pacFIC - Patent Foramen Ovale Study
Randomised Controlled Trial Comparing the Safety and EfficAcy of the Cocoon PFO Occluder Versus Amplatzer PFO ClosurE Device for Percutaneous Closure of Patent Foramen Ovale in Patients With a History of Stroke or Transient Ischemic Attack A Non-Profit, Single-blind, Investigator Driven Trial
Who cites it
72 citing papers in PubMed, 3 syntheses or guidelines pooled it, 183 citations in OpenAlex.
- Advances in Primordial, Primary, and Secondary Prevention of Stroke in Diverse Populations.Stroke · 2024Pooled it
- Deep Vein Thrombosis and Pulmonary Embolism Among Patients With a Cryptogenic Stroke Linked to Patent Foramen Ovale-A Review of the Literature.Frontiers in neurology · 2020Pooled it
- Closure, Anticoagulation, or Antiplatelet Therapy for Cryptogenic Stroke With Patent Foramen Ovale: Systematic Review of Randomized Trials, Sequential Meta-Analysis, and New Insights From the CLOSE Study.Journal of the American Heart Association · 2018Pooled it
- Thrombectomy and Extraction of Patent Foramen Ovale Occluder With Repair of Atrial Septum: A Minimally Invasive Approach.CJC pediatric and congenital heart disease · 2026Article
- Incremental Predictive Value of the Non-HDL-C/HDL-C Ratio for Cryptogenic Stroke in Patients with Patent Foramen Ovale.Journal of cardiovascular development and disease · 2026Article
- High-density contrast echocardiography for patent foramen ovale assessment: sensitivity and relationship with invasively measured shunt severity and atrial septum morphology.Echo research and practice · 2026Article
- Comparison of the Antithrombotic Strategy Implemented to Prevent Early Recurrence before Closure of Patent Foramen Ovale.Cerebrovascular diseases (Basel, Switzerland) · 2026Article
- Article
- Article
- Caught Red-Handed - A Cryptogenic Stroke Culprit Passes Through the Patent Foramen Ovale.Circulation reports · 2025Article
- Contrast-Enhanced Transcranial Doppler for Detecting Residual Leaks-A Single-Center Study on the Effectiveness of Percutaneous PFO Closure.Journal of clinical medicine · 2025Article
- Paradoxical Thalamic Infarction via Patent Foramen Ovale in an Athletic Young Adult: A Case Report.Cureus · 2025Article
- Percutaneous Closure of Patent Foramen Ovale and Atrial Septal Defect in Athletes: A Study With a Long-Term Follow-Up.Scandinavian journal of medicine & science in sports · 2025Article
- Treatment of patent foramen ovale.EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology · 2025Review
- PFO-ACCESS: Augmenting Communications for Medical Care or Closure in the Evaluation of Patients With Stroke With Cardiac Shunts.Stroke (Hoboken, N.J.) · 2025Article
- Predictors of recurrent ischemic stroke: anatomical characteristics of patent foramen ovale.Frontiers in cardiovascular medicine · 2025Article
- Case Report: Is there an age cutoff beyond which PFO closure should not be offered?Frontiers in cardiovascular medicine · 2025Article
- Patent Foramen Ovale (PFO): History, Diagnosis, and Management.Reviews in cardiovascular medicine · 2024Review
- Yield of Echocardiography with Bubble Studies Among Acute Ischemic Stroke Patients.Journal of clinical medicine · 2024Article
- Influence of procedural timing on the preventive yield of percutaneous patent foramen ovale closure.Open heart · 2024Article
12 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
7 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWe conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) comparing patent foramen ovale (PFO) closure, anticoagulation, and antiplatelet therapy to prevent stroke recurrence in patients with PFO-associated cryptogenic stroke. METHODS AND
resultsWe searched Medline, Cochrane Library, and EMBASE through March 2018. The primary outcome was stroke recurrence. Pooled incidences, hazard ratios, and risk ratios (RRs) were calculated in random-effects meta-analyses. PFO closure was associated with a lower risk of recurrent stroke compared with antithrombotic therapy (antiplatelet therapy or anticoagulation: 3560 patients from 6 RCTs; RR=0.36, 95% CI: 0.17-0.79; I
conclusionsPFO closure is superior to antithrombotic therapy to prevent stroke recurrence after cryptogenic stroke. The annual absolute risk reduction of stroke was low, but it has to be tempered by a substantial time at risk (at least 5 years) in young and middle-aged patients. PFO closure was associated with an increased risk of atrial fibrillation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.